Ranitidine

Duloxetine, sold under the brand name Cymbalta, was recalled due to the presence of a potentially cancer-causing nitrosamine, N-nitrosoduloxetine. Over 233,000 bottles were recalled by Rising Pharmaceuticals, with the FDA classifying it as a class II risk, indicating temporary or reversible health consequences. Duloxetine, an SNRI, is used to treat depression, pain, and anxiety by increasing neurotransmitters in the brain.

Pfizer faces lawsuits over Depo-Provera's link to meningiomas, Zantac's NDMA contamination leading to a $250 million settlement, and Protonix's alleged kidney damage. These cases highlight challenges in balancing pharmaceutical innovation with patient safety.

GSK invests up to $800 million to expand its Marietta, Pennsylvania facility, adding sterile vaccine, medicine, and clinical trial drug production, and creating over 200 jobs. The site will feature advanced technologies and be LEED Silver certified. Pennsylvania supports the expansion with a $21 million investment. Despite declining vaccine demand, GSK has invested nearly $1.3 billion in U.S. manufacturing since 2017.

GSK delivered Q3 sales and core operating profit growth, with strong specialty medicines offsetting lower vaccine sales. The pipeline strengthened with 11 positive phase III trials and 5 major product launches planned for next year. Zantac litigation was resolved, aligning with 2024 guidance and bolstering confidence in 2026 and 2031 outlooks. Forward-looking statements are subject to risks and uncertainties.

GSK's Q3 sales growth slowed due to a 15% drop in vaccine revenue, but HIV and cancer treatments offset declines. The company reiterated full-year forecasts despite cutting vaccine division outlook twice this year. Operating profit fell 86% to £189m, impacted by a £1.8bn charge for settling US Zantac lawsuits.

GSK Q3 2024 results: £8.0 billion sales (-2% AER, +2% CER), driven by Specialty Medicines (+19%) offsetting Vaccines (-15%). Core operating profit +5%, Core EPS +5%. R&D progress includes EU approval for Arexvy, HIV PrEP effectiveness, and oncology breakthroughs. 2024 guidance confirmed: 7-9% turnover growth, 11-13% Core operating profit growth, 10-12% Core EPS growth, excluding COVID-19 solutions.

AstraZeneca to pay $2B to CSPC for a cardiovascular drug, Astellas Pharma licenses gene therapy from AviadoBio, Merck partners with Mestag Therapeutics for fibrosis treatments, Insitro signs three agreements with Eli Lilly for metabolic diseases, MiNK Therapeutics and Autonomous Therapeutics collaborate on metastatic tumors, Bayer and MOMA Therapeutics partner in oncology, Wonderskin names 5W Public Relations as AOR, Eversana signs with Oracle Argus Cloud, Qinotto and Eli Lilly collaborate, Onspire Health acquires Aesthetic Brand Marketing, Reunion Neuroscience partners with Seleni Institute, Danco Laboratories to seek FDA approval for Mifeprex use in miscarriages, Exact Sciences' Cologuard Plus wins FDA approval, Boehringer Ingelheim's survodutide gets Breakthrough Therapy designation, Lunds & Byerlys recalls Lone Star Dip, Kezar Life Sciences' zetomipzomib development halted by FDA, Bayer's elinzanetant NDA accepted by FDA, Biogen's felzartamab gets Breakthrough Therapy Designation, Black Diamond Therapeutics to cut jobs, Upstream Bio targets $182M for IPO, City Therapeutics launches with $135M, Purespring Therapeutics raises $105M, Judo Bio launches with $100M, Orasis Pharmaceuticals raises $78M, CAMP4 Therapeutics targets $67M for IPO, Basecamp Research closes $60M Series B, Arda Therapeutics raises $43M Series A, Crinetics Pharmaceuticals announces public offering, GSK to pay $2.2B to settle Zantac lawsuits, Scholar Rock's SMA drug shows muscle function improvement, CDC to screen travelers due to Marburg virus outbreak in Rwanda, Ad Council, AMA, and CDC launch flu vaccination campaign, Sage Therapeutics' Sage-718 fails in Alzheimer's study, WeightWatchers adds GLP-1 obesity treatments, Gritstone Bio files for Chapter 11, BioPharmCatalyst launches AI-powered chatbot Aiden, Otsuka Precision Health and Amalgam Rx launch Alzheimer's app Elevmi, PatientPoint unveils interactive communication solution, Curia rebrands, Switzerland's COMCO terminates Novartis investigation, Bluebird Bio's Skysona linked to blood cancer in seven children, Solera Health rebrands, HearingLife launches pickleball sweepstakes, Alfasigma launches Morpho brand, Healthy Minds Innovations launches Our World Of Emotions campaign.

Baxter increases IV fluid allocations amid shortages; GSK to settle 80,000 Zantac lawsuits for up to $2.2B.

GSK shares rose 5% after resolving 93% of Zantac cancer lawsuits for up to $2.2 billion. Plaintiffs unanimously recommend accepting the settlement, expected by H1 2025. GSK denies Zantac increases cancer risk and settles with Valisure for $70 million, pending DOJ approval.

GSK will pay up to £1.7billion to settle claims that its heartburn drug Zantac caused cancer, ending a five-year legal saga.